Automated cell cultures market seen reaching $11.58 billion by 2030

The Business Research Company says the automated cell cultures market will grow from $7.02 billion in 2025 to $11.58 billion by 2030, driven by biopharmaceutical production, lab automation and cell and gene therapy manufacturing. North America leads now, while Asia-Pacific is projected to grow fastest.

Why it matters: - Automated cell culture is becoming core infrastructure for biopharma research and manufacturing. - The market’s projected growth points to more demand for reproducible, scalable and sterile lab workflows. - The shift could speed up drug discovery, cell and gene therapy production and biologics manufacturing.

What happened: - The Business Research Company published its Automated Cell Cultures Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will rise from $7.02 billion in 2025 to $7.78 billion in 2026. - The report projects the market will reach $11.58 billion by 2030. - The report estimates a 10.8% CAGR for 2025 to 2026 and a 10.5% CAGR from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report says it covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Automated cell cultures use robotics and automated systems for tasks such as seeding, feeding and harvesting cells. - These systems reduce manual labor and improve consistency, reproducibility and scalability. - Automation also supports sterile environments and more reliable outcomes in cell culture workflows. - The report links historical growth to biopharmaceutical research, standardized protocols, drug discovery, modular automation and academic life science research. - Future growth is expected to be driven by investment in cell and gene therapy manufacturing, high-throughput screening, personalized medicine, lab automation and scalable biologics production. - Key trends include fully automated cell culture platforms, robotic liquid handling systems, closed-system cell processing and tighter reproducibility and sterility controls. - The report highlights market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables as 2026 report enhancements. - The report is available with a free sample at Download a free sample of the report. - The full report is available at View the full market report.

Between the lines: - Rising biopharmaceutical output is the clearest demand signal behind the market forecast. - Sartorius said in July 2025 that worldwide sales of biopharmaceutical drugs rose about 9% to $458 billion in 2024. - Sartorius said biopharmaceutical drugs accounted for 41% of the total pharmaceutical market in 2024, up from 40% in 2023. - The report’s emphasis on closed systems and sterility suggests buyers are prioritizing quality control as automation spreads.

What’s next: - The market is expected to keep expanding as more labs and manufacturers adopt automated workflows. - The fastest gains are likely to come from Asia-Pacific as biotechnology investment and healthcare capacity grow. - The report points to continued development in robotic liquid handling, closed-system processing and fully automated platforms.

The bottom line: - Automated cell culture is moving from a niche lab upgrade to a broader manufacturing and research requirement, and the market outlook reflects that shift.